Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (NASDAQ: SNWV) is a medical technology company that focuses on patented, non-invasive directed energy systems used in advanced wound care and tissue regeneration. Its press releases emphasize research, development, and commercialization of medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures, as well as applications in orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
The SNWV news feed highlights quarterly and annual financial results, including revenue trends, gross margin, operating income, and non-GAAP measures such as EBITDA and Adjusted EBITDA. Investors can follow updates on record quarterly revenues, changes in revenue mix driven by UltraMIST systems and consumables, and management commentary on market conditions in the wound care space.
News items also cover business updates and reimbursement developments. Sanuwave has issued releases discussing proposed and final rules from the Centers for Medicare & Medicaid Services (CMS) for the Physician Fee Schedule, particularly reimbursement for CPT code 97610 associated with UltraMIST procedures. These updates explain how reimbursement levels for physician offices, home visits, long-term care, and hospital settings relate to the company’s expectations.
Additional coverage includes strategic and corporate events, such as a secured credit facility with JPMorgan Chase Bank, N.A. used to refinance a prior debt facility, a license and option agreement related to intravascular shockwave patents, and participation in healthcare industry conferences. The news stream also reports on governance and executive changes disclosed in Form 8-K filings, as well as announcements of conference calls to discuss financial results.
By reviewing the SNWV news page, readers can see how Sanuwave communicates its financial performance, reimbursement environment, capital structure decisions, and ongoing activities in advanced wound care and regenerative medicine.
SANUWAVE Health (OTCQB: SNWV) has announced a collaboration with NASA to tackle bacterial biofilms in the Water Recovery System (WRS) essential for long-duration space missions. Utilizing their proprietary shockwave technology, SANUWAVE aims to prevent biofilm formation that poses risks to water systems used in human habitats on the Moon and Mars. This partnership is significant for ensuring clean water for future lunar and Martian missions, and SANUWAVE's innovative solutions may extend to various commercial applications in water cleaning and disinfection.
SANUWAVE Health (OTCQB:SNWV) has announced updated dial-in instructions for its conference call on July 15, 2021, at 4:30 PM ET. The call will cover recent business activities, SEC filing updates, and strategic initiatives. Participants can join by calling Toll-Free: 844-407-9500 or International: 862-298-0850. A replay will be available through July 22, 2021, using Toll-Free: 877-481-4010 and International: 919-882-2331 with the passcode 42095. SANUWAVE focuses on advanced wound care and regenerative medicine.
SANUWAVE Health (OTCQB:SNWV) will host a conference call on July 15, 2021, at 4:30pm ET, to discuss recent business activities, SEC filings, and strategic initiatives. All interested parties can access the call by dialing 678-578-0113 in the U.S. SANUWAVE focuses on developing next-generation wound care products utilizing patented energy transfer technologies aimed at enhancing wound healing and tissue regeneration. Further information about SANUWAVE can be found at www.SANUWAVE.com.
SANUWAVE Health (OTCQB:SNWV) announced on July 2, 2021, that its shares will transition to pink sheets due to late financial filings with the SEC. The CEO, Kevin Richardson, attributed the delays to accounting system issues, asserting they are being resolved and that current filings are forthcoming. The company remains optimistic about its operations, citing a distribution agreement in Latin America and strong clinical study results. Their UltraMIST systems are seeing record sales, and the recent relaunch of the ENERGY FIRST platform is gaining traction, suggesting potential growth ahead.
SANUWAVE Health, Inc. (OTCQB:SNWV) recently reported promising results from a clinical case series on its dermaPACE System, an FDA-cleared treatment for diabetic foot ulcers. The study, published in the American Journal of Nursing Science, showed a 25% increase in tissue oxygen saturation and a 46.7% full wound closure rate among patients over four weeks. This signifies the system's effectiveness in enhancing wound healing and could transform management strategies for chronic wounds in diabetic patients, impacting around 30.3 million Americans.
SANUWAVE Health, Inc. (OTCQB:SNWV) announces its participation in the LD Micro Invitational XI conference, scheduled for June 8-10, 2021. CEO Kevin Richardson will present on June 10, 2021, at 4:30 p.m. EDT. The presentation will cover SANUWAVE's innovative wound care solutions that leverage patented biological response-activating technologies. Interested parties can access a live audio webcast at this link. The company focuses on non-invasive medical systems for healing and regeneration in various medical fields.
SANUWAVE Health, Inc. (OTCQB:SNWV) has announced a distribution agreement with Grupo Suprimed to market and sell its dermaPACE System in Brazil's private healthcare sector. This agreement aims to strengthen SANUWAVE's presence in Brazil, the largest healthcare market in Latin America, which has a vast network of hospitals and healthcare professionals. SANUWAVE’s CEO highlighted the potential for improving healthcare quality and lowering costs through this partnership, while Grupo Suprimed is recognized as a significant distributor of medical products in the region.
SANUWAVE Health (OTCQB:SNWV) has engaged MZ Group to enhance its investor relations and financial communications strategy. This partnership aims to boost the company's visibility in the investment community, particularly for its Energy First wound care product line. The U.S. diabetic foot ulcer market, valued at $15 billion, underscores the growth potential. The firm will assist in roadshows and promote SANUWAVE's differentiating technologies, including non-contact ultrasound devices and biologics. Leadership anticipates significant revenue growth due to positive reimbursement dynamics.
SANUWAVE Health (OTCQB:SNWV) will present at the Q2 Virtual Investor Summit on May 18, 2021, starting at 11:45 a.m. ET. Kevin Richardson, the company's CEO, will engage in one-on-one meetings with investors during this event. Registration is required for participation. SANUWAVE specializes in the development of advanced wound care medical systems that facilitate the repair and regeneration of skin and vascular structures. The company’s focus is on innovative solutions using non-invasive technologies for various medical applications.
SANUWAVE Health (OTCQB:SNWV) announced the issuance of 11 new patents, increasing its total to 150 active patents and applications. These patents enhance the company's proprietary shockwave and ultrasound technologies for medical and non-medical applications. Key patents include methods for tissue disinfection, clot treatment, and meat processing. The company continues to focus on developing its patented technologies and monetizing non-wound care applications. CEO Kevin Richardson highlighted that these patents strengthen SANUWAVE's competitive position in the advanced wound care market.